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Abstract The specialty of cardiac surgery has evolved
substantially over the last 50 years, and surgical
procedures that seemed impossible then are now
commonly encountered in hospitals throughout the
world. The latest development in this ever-evolving
field is minimally invasive and robot-assisted proce-
dures. In this article we will review the surgical out-
comes reported for different series of procedures in
cardiac surgery.
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Introduction
Throughout the short history of cardiac surgery, which
is just over 100 years, surgeons worldwide have been
determined to develop, perform, perfect, and improve
cardiac operations. Our forefathers set the bar high by
performing magnificent cardiac operations with excel-
lent long-lasting results. In this ever-evolving field the
goal now has become to reproduce these results using
less invasive techniques, directed toward reducing
complications, accelerating the recovery process, and
improving patient satisfaction. Every other surgical
discipline has introduced minimally invasive tech-
niques and many of these involve totally endoscopic
robotic surgery. The current end result is multidisci-
plinary involvement using the da Vinci robotic system
to effect precise surgical tele-manipulation.
In 1998, Carpentier et al. [1] performed the first
mitral valve repair utilizing an early prototype of the
da Vinci system. Mohr expanded this early effort in
Europe and our surgeons were fortunate to have been
part of this effort. In May of 2000 our team performed
the first complete robotic mitral repair with da Vinci in
North America, which included a leaflet resection,
reconstruction, and an annuloplasty. Since then coro-
nary revascularizations, MAZE procedures, left ven-
tricular lead placements, congenital heart operations,
and aortic valve replacements have been performed
successfully with this system and in substantial num-
bers. Although recent clinical data show there are
benefits to robotic cardiac surgery, comparisons to
conventional sternotomy operations are scarce. Surgi-
cal outcomes must be the focus of demonstration of
continued progress.
Mitral valve surgery
The first Food and Drug Administration (FDA) safety
and efficacy trial, was conducted at East Carolina
University (ECU) in 2000, and included 20 patients [2].
Leaflet resections, sliding plasties, chordal transfers,
neochord insertions, and annuloplasties were all
performed successfully. This initial study revealed that
although operating times were longer than for con-
ventional mitral valve surgery, the results were very
good. There were no device-related complications. The
postoperative hospital stay averaged four days and all
patients returned to normal activity within one month
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after surgery. Finally, early postoperative echocardio-
grams after 3 months revealed that none of the patients
had more than trace mitral regurgitation (MR).
These initial results were encouraging and prompted
a phase II multicenter FDA trial, which was completed
in 2002 [3]. In this trial a total of 112 patients were
enrolled at ten different institutions. Again all types of
repair were performed. Nine patients (8%) had grade 2
or higher mitral regurgitation, and six patients (5%)
required a reoperation. Although we regarded this
initial number of reoperations as relatively high, the
failures were distributed evenly among centers, with
some having performed fewer than ten procedures.
Most re-operations occurred in the early part of our
now 300 patient series. In this initial multi-center series
there were no deaths, strokes, or device-related com-
plications, establishing the safety and efficacy for this
method. These results prompted the FDA to approve
the da Vinci system in November of 2002 for use in
mitral valve-repair surgery.
The initial results from the first 200 ECU cases were
presented at the American Heart Association Meeting
in November of 2005 [4]. The average age of this pa-
tient cohort was 57 ± 0.9 years. Average operating
times were: total operative = 285 min, cardiopulmo-
nary bypass (CPB) = 156 min, and cross clamp
(XC) = 119 min. Again repairs included quadrangular
resections, sliding plasties, chordal transfers, chordal
shortening, neochord insertion, and annuloplasties.
There was one (0.5%) operative death secondary to a
protamine reaction and no device or perfusion-related
complications. There were also three (1.5%) hospital
deaths from pulmonary and renal maladies. The hos-
pital length of stay averaged 4.8 ± 0.2 days. Postoper-
ative echocardiograms showed that 187 patients
(93.5%) had no MR; six patients (3%) had trace MR,
five patients (2.5%) had moderate MR, and two pa-
tients (1%) had systolic anterior motion of the anterior
leaflet. Five patients (2.5%) required a reoperation for
failed repairs, which were related either to an annu-
loplasty band dehiscence or progressive valvular dis-
ease. No failures were related to either a chordal
insertion/transfer or leaflet dehiscence. We have
repaired 60 mitral valves with bileaflet prolapse
(Barlow’s) without any significant residual leak.
Tatooles et al. [5] reported excellent results for 25
patients with no deaths, device-related complications,
strokes, reoperations for bleeding, or incisional con-
versions. One patient had a transient ischemic attack
seven days after surgery. Their average CPB and XC
times (±SD) were 126.6 ± 25.7 and 87.7 ± 20.9 min,
respectively. A total of 21 patients (84%) were extu-
bated in the operating room, and the average length of
stay was 2.7 days. For this aggressive discharge proto-
col, however, readmission was 28% and two patients
required interval mitral valve replacements. When
presented nationally there was discussion about this
high rate of recidivism.
Another small series of 32 patients was reported by
Jones et al. [6], who reported the safety of the proce-
dure at a community hospital. They performed isolated
mitral valve repairs and isolated mitral valve repairs
combined with tricuspid valve repairs (n = 3). More-
over in two patients a MAZE procedure (n = 2) was
used to treat atrial fibrillation. There were two deaths
and neither was device related. Complications included
three reoperations for repair failures, a stroke (n = 1),
a groin lymphocele (n = 1), and a pulmonary embolism
(n = 1).
More recently, Folliguet et al. [7] compared roboti-
cally assisted mitral valve repairs (n = 25) with a mat-
ched cohort undergoing a repair via sternotomy
(n = 25). Hospitalization was statistically significant
shorter for the robotic group than for the sternotomy
group (7 compared with 9 days). There were no other
result differences between groups. In October of 2006,
Murphy and associates [8] reported their robotic mitral
valve surgery experience with 127 patients. There were
five conversions to median sternotomy, and one patient
was converted to a mini-thoracotomy, resulting in 121
patients on whom operations were conducted roboti-
cally. Seven patients underwent a mitral replacement
and 114 patients underwent repairs. Although annu-
loplasty bands and sutures were placed by tele-manip-
ulation, knots were tied extracorporeally by an assistant
surgeon. There was one in-hospital death, one late
death, two strokes, and 22 patients developed postop-
erative atrial fibrillation. Transfusion of blood products
was required in 37 (31%) patients. Two patients
required re-operation for repair failures (1.7%).
Post-discharge echocardiograms were available for 98
patients with a mean follow-up of 8.4 ± 8.1 months. A
total of 87 (88.0%) patients had no MR, 8 (8.2%)
patients had 1 + MR, and 3 (3.1%) patients had
2 + MR. Again, this series validates previous reports
demonstrating that robotic mitral valve surgery is safe
and has excellent short-term results. Studies with longer
follow-up are needed, however, and surgeons must
aspire to even more endoscopic mitral operations using
da Vinci or another tele-manipulation system.
Atrial fibrillation surgery
There have been few case reports [9–11] of patients
undergoing combined robotic mitral valve and atrial
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fibrillation (MV/AF) surgery to demonstrate these
procedures are safe. Only one small series of patients
have undergone robotic MV/AF surgery. The results
were published by Reade et al. [12] for 16 patients after
combined MV/AF surgery using the Flex-10 micro-
wave catheter (Guidant, Indianapolis, IN, USA) for
left atrial ablation. The ablation added 42 ± 16 min to
the MR = V repair and 1.3 days to hospitalization. At
6 months follow-up eleven patients (73%) were in
sinus rhythm, three (20%) were paced, and one (7%)
was in atrial fibrillation.
Coronary revascularization
The range of robot-assisted coronary operations ranges
from robotic internal thoracic artery (ITA) takedowns
but with a hand-sewn anastomosis, performed on or
off-pump, via either a median sternotomy or a mini-
thoracotomy, to the ‘‘so-called’’ totally endoscopic
coronary artery bypass (TECAB) procedure. Early
reports demonstrated the feasibility and safety of har-
vesting the ITA with the da Vinci system. Acceptable
learning curves and harvest times of <30 min were
achieved after the technique was mastered [13–15].
There have been many early case reports and small
series of robot-assisted coronary operations. Not until
recently did larger series from experienced centers
emerge, however. Subramanian et al. [16] reported 30
patients undergoing robot-assisted multi-vessel off-
pump CABG via a mini thoracotomy. The average
number of grafts was 2.6. There were no mortalities
(30-day follow-up) and 29 patients (97%) were extu-
bated in the operating room. Two patients required re-
exploration for bleeding, and one patient required a
sternotomy for further grafting. Half of the patients
were discharged within 24 h and only two patients
stayed in the hospital more than 3 days.
Using a similar surgical technique, Turner and Sloan
[17] reported 70 patients with no operative mortality.
The average operating time was 4 h, however, and
there was a clear learning curve (operating times 5 h
and 56 min for the first ten cases and 3 h and 52 min
for the last ten cases). Complications included
re-exploration for bleeding (n = 2, 2.8%), atrial fibril-
lation (n = 6, 8.5%), and infections (n = 2, 2.8%). All
were extubated within 24 h of surgery and the average
length of stay was 5.7 days. The largest single institu-
tion series was that of Srivastava et al. [18], with 150
patients undergoing robotic assisted bilateral IMA
harvest and off-pump CABG via mini thoracotomy.
The average number of arterial grafts was 2.6 ± 0.8 per
patient. There were no mortalities, myocardial infarc-
tions, strokes, or wound infections. Re-exploration for
bleeding was required for four patients, however. The
mean postoperative length of stay was 3.6 ± 2.9 days.
In the prospective multi-center TECAB Argenziano
et al. [19] described 98 patients requiring single-vessel
ITA-LAD grafting who were enrolled at 12 centers.
Thirteen patients (13%) were excluded intraopera-
tively because of inability to perform the operation.
Mean CPB and arrest times for the other 85 patients
was 117 ± 44 and 71 ± 26 min, respectively, with
length of stay averaging 5.1 ± 3.4 days. Although there
were no deaths or strokes, there was one early rein-
tervention, one myocardial infarction, and five (6%)
conversions to the open technique. Short-term arte-
riographic follow-up at 3 months (n = 76) revealed
significant stenosis (>50%) or occlusion in six patients.
Although overall freedom from re-intervention was
91%, conversions and anastomotic complications ren-
dered the results somewhat disappointing. Despite
sporadic failures in early series of both on and off-
pump robot-assisted CABG operations, use of the
method is increasing. Perhaps multi-vessel small
thoracotomy bypass grafting, facilitated by robotic
graft harvesting, will be the answer. Combination of
percutaneous revascularization and LAD robotic
grafting remains attractive for use in selected patients.
Irrespective of the method, long-term follow-up is still
necessary to determine if these techniques are com-
parable with the excellent results achieved by use of
median sternotomy.
Left ventricular lead placement
Numerous prospective studies have demonstrated that
biventricular (BiV) pacing improves ventricular func-
tion, exercise capacity, and quality of life in patients
with congestive heart failure and delayed interventric-
ular conduction. A recent meta-analysis also revealed
survival improved after BiV pacing. Although leads are
most often placed by use of transvenous techniques, 15
to 25% of transvenous implantations fail. At this point
surgical intervention is required. Early reports by
DeRose et al. [20] attested to the efficacy of robot-
assisted left ventricular lead implantation. They
reported results for thirteen patients, six (46%) of
whom had a previous CABG, with no complications or
technical failures. Navia’s series, combining minimally
invasive (via mini thoracotomy) and robotic/endoscopic
LV lead placements, included 41 patients without
mortality, intraoperative complications, or implanta-
tion failures [21]. This approach is very attractive and
could become the preferred technique, because sur-
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geons should be able to determine the best epicardial
site for implantation by mapped stimulation. This could
result in markedly increased lead placement success
and improved ventricular function compared with cur-
rent transvenous techniques. A randomized study
comparing both techniques is in progress.
Congenital surgery
A few congenital cardiac conditions are amenable to
minimally invasive or robotic repairs. del Nido and
Suematsu [22] summarized their early robotic con-
genital cardiac surgery results. A robot was used at
the Boston Children’s Hospital mainly for manage-
ment of extracardiac lesions, including the patent
ductus arteriosus (PDA) and vascular rings [23]. Their
average age for PDA closures (n = 15) or vascular ring
repairs (n = 6) was 8.3 ± 4.7 years. Total operating
times were somewhat long at 170 ± 46 min (PDA) and
167 ± 48 min (vascular ring). There were no compli-
cations and only one conversion to a thoracotomy. All
patients were extubated in the operating room with a
mean postoperative hospital stay of 1.5 days.
Again robotic surgery for intra-cardiac lesions has
been limited. Morgan et al. [24] reported eleven
patients undergoing robotic atrial septal defect (ASD)
repairs and five having closure of a patent foramen
ovale. They demonstrated improved quality of life in
eight variables after robotic procedures compared
with patients having either a sternotomy or mini tho-
racotomy. There were no group differences between
time to return to work or length of hospitalization,
however.
Summary
Although robotic cardiac surgery is still evolving, early
results from experienced centers are encouraging and
are comparable with those from traditional cardiac
surgical techniques. Demonstrated advantages include
fewer blood transfusions, reduced hospitalization, fas-
ter return to normal daily activity, and improved
quality of life. As technology continues to improve,
these procedures will continue to become more com-
mon among cardiac centers. Evolution of adjunctive
devices and techniques will also improve access to, and
workspace in, confined intra-cardiac operations. To
determine if robotic techniques could become the new
standard in cardiac surgery, long-term results are
imperative.
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